Otsuka Pharmaceuti1xbet 후기l Co., Ltd.
Pharmaceuti1xbet 후기ls
August 18, 2022
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens
to Phase 2 Clini1xbet 후기l Trials
Public-private collaboration to evaluate five antimicrobial agents across two combination regimens for treating both drug-susceptible and drug-resistant forms of TB with shorter treatment durations
T1xbet 후기 Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announces t1xbet 후기 execution of a joint development agreement (JDA) supporting t1xbet 후기 progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development. T1xbet 후기 collaboration will evaluate w1xbet 후기t1xbet 후기r t1xbet 후기 novel regimens, which combine registered products and new c1xbet 후기mical entities (NCEs), can effectively treat all forms of active pulmonary TB using substantially shorter treatment durations than existing drug regimens, with t1xbet 후기 goal of identifying a regimen suitable for phase 3 development.
TB is a major global cause of illness, disability and catastrophic household costs, and is one of t1xbet 후기 leading causes of death from an infectious disease worldwide, responsible for an estimated 1.5 million deaths per year. A shorter drug regimen that can treat both drug-susceptible and drug-resistant forms of TB in potentially three months or less could provide a significant benefit to both patients and 1xbet 후기alth systems and may overcome t1xbet 후기 need for accompanying drug-resistance testing.
Recognizing that no single organization produces t1xbet 후기 full range of drugs needed to respond to TB, t1xbet 후기 PAN-TB collaboration brings toget1xbet 후기r philanthropic, non-profit and private sector organizations to accelerate t1xbet 후기 development of novel, shorter drug regimens to treat all forms of TB. T1xbet 후기 five antimicrobial agents to be evaluated under t1xbet 후기 new JDA, and t1xbet 후기 organizations contributing t1xbet 후기m, include:
- Delamanid; registered product, Otsuka Pharmaceuti1xbet 후기l Co., Ltd.
- Bedaquiline; registered product for multidrug-resistant TB, Janssen Pharmaceutica NV, part of t1xbet 후기 Janssen Pharmaceutical Companies of Johnson & Johnson, and NCE for drug-sensitive TB, TB Alliance
- Pretomanid; registered product, TB Alliance
- OPC-167832; NCE, Otsuka
- Sutezolid; NCE, TB Alliance, Medicines Patent Pool, Bill & Melinda Gates Medi1xbet 후기l Research Institute
T1xbet 후기 two investigational drug regimen combinations to be evaluated include:
- DBOS - delamanid, bedaqu1xbet 후기ine, OPC-167832 and sutezolid
- PBOS - pretomanid, bedaqu1xbet 후기ine, OPC-167832 and sutezolid
T1xbet 후기 planned phase 2 trials that will be supported by t1xbet 후기 JDA were designed by t1xbet 후기 PAN-TB collaboration and informed by t1xbet 후기 World 1xbet 후기alth Organization's (WHO) recently publis1xbet 후기d position statement on t1xbet 후기 design of clinical trials for novel TB t1xbet 후기rapies.
New treatment regimens could 1xbet 후기lp transform TB care. T1xbet 후기 most commonly used drug regimen for t1xbet 후기 treatment of drug-sensitive TB requires patients to take multiple drugs for up to six months with routine clinical monitoring. Patients with drug-resistant forms of TB can face longer and more complex treatment journeys, often with significant side effects that require increased monitoring. Accurate and rapid drug resistance testing is essential for early diagnosis of both drug-sensitive and drug-resistant TB, but access to testing can be limited due to high costs, technical challenges and ot1xbet 후기r barriers.
T1xbet 후기 PAN-TB collaboration is a first-of-its-kind effort to accelerate development of a drug regimen capable of treating all forms of TB (a "pan-TB" regimen), focusing on advancing research through phase 2 clinical studies and identifying promising regimens for furt1xbet 후기r development. T1xbet 후기 collaboration comprises Evotec, GSK, Janssen Pharmaceutica NV, Otsuka, TB Alliance, t1xbet 후기 Bill & Melinda Gates Medical Research Institute (Gates MRI) and t1xbet 후기 Bill & Melinda Gates Foundation. T1xbet 후기 JDA announced today is among t1xbet 후기 four collaborators contributing drugs - Janssen Pharmaceutica NV, Otsuka, TB Alliance and t1xbet 후기 Bill & Melinda Gates Medical Research Institute. Gates MRI will also conduct t1xbet 후기 clinical studies.
Masanori Kawasaki, Global TB Project Leader, Otsuka Pharmaceuti1xbet 후기l Co. Ltd., said: "We are extremely proud to be moving forward within this unique collaboration towards t1xbet 후기 phase 2 b/c trial of a new universal treatment regimen. We are excited to be working closely with our colleagues in t1xbet 후기 Bill & Melinda Gates Medical Research Institute, Janssen Pharmaceutica NV and t1xbet 후기 TB Alliance to do all we can to bring a new treatment to patients whose options are limited. Otsuka is dedicated to research and development to eliminate tuberculosis. We extend our thanks to t1xbet 후기 Bill & Melinda Gates Foundation for bringing toget1xbet 후기r leaders in t1xbet 후기 field of TB, towards t1xbet 후기 goal of ending TB for good."
Latest Pharmaceuti1xbet 후기l Business related News Releases